A 12-WEEK DOUBLE-BLIND MULTICENTER STUDY OF PAROXETINE AND IMIPRAMINEIN HOSPITALIZED DEPRESSED-PATIENTS

Fifty-seven inpatients with major depression (DSM-III-R) entered a 12- week study comparing paroxetine and imipramine. Trends (not reaching s tatistical significance) in favour of paroxetine were seen on the Hami lton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depressi on Rating Scale (MADRS). The UKU Side Effect Rating Scale showed a sig nificant difference in favour of paroxetine on reduced salivation. Glo bal evaluation of side effect symptoms showed that significantly more paroxetine patients had no side effects, both in the investigators' an d the patients' opinion. These results are in line with previous findi ngs of paroxetine being an effective and well tolerated antidepressant .